Literature DB >> 27587540

Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap.

J Jason Morton1, Gregory Bird2, Yosef Refaeli2,3, Antonio Jimeno4,3,5.   

Abstract

Cancer research has long been hampered by the limitations of the current model systems. Both cultured cells and mouse xenografts grow in an environment highly dissimilar to that of their originating tumor, frequently resulting in promising treatments that are ultimately clinically ineffective. The development of highly immunodeficient mouse strains into which human immune systems can be engrafted can help bridge this gap. Humanized mice (HM) allow researchers to examine xenograft growth in the context of a human immune system and resultant tumor microenvironment, and recent studies have highlighted the increased similarities in attendant tumor structure, metastasis, and signaling to those features in cancer patients. This setting also facilitates the examination of investigational cancer therapies, including new immunotherapies. This review discusses recent advancements in the generation and application of HM models, their promise in cancer research, and their potential in generating clinically relevant treatments. This review also focuses on current efforts to improve HM models by engineering mouse strains expressing human cytokines or HLA proteins and implanting human bone, liver, and thymus tissue to facilitate immune cell maturation and trafficking. Finally, we discuss how these improvements may help direct future HM model cancer studies. Cancer Res; 76(21); 6153-8. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27587540      PMCID: PMC5093075          DOI: 10.1158/0008-5472.CAN-16-1260

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

Review 1.  Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.

Authors:  M F Sanmamed; C Chester; I Melero; H Kohrt
Journal:  Ann Oncol       Date:  2016-02-23       Impact factor: 32.976

2.  Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

Authors:  Miguel F Sanmamed; Inmaculada Rodriguez; Kurt A Schalper; Carmen Oñate; Arantza Azpilikueta; Maria E Rodriguez-Ruiz; Aizea Morales-Kastresana; Sara Labiano; Jose L Pérez-Gracia; Salvador Martín-Algarra; Carlos Alfaro; Guillermo Mazzolini; Francesca Sarno; Manuel Hidalgo; Alan J Korman; Maria Jure-Kunkel; Ignacio Melero
Journal:  Cancer Res       Date:  2015-06-25       Impact factor: 12.701

Review 3.  Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

Authors:  Douglas Marvel; Dmitry I Gabrilovich
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

4.  Predominant development of mature and functional human NK cells in a novel human IL-2-producing transgenic NOG mouse.

Authors:  Ikumi Katano; Takeshi Takahashi; Ryoji Ito; Tsutomu Kamisako; Takuma Mizusawa; Yuyo Ka; Tomoyuki Ogura; Hiroshi Suemizu; Yutaka Kawakami; Mamoru Ito
Journal:  J Immunol       Date:  2015-02-23       Impact factor: 5.422

5.  Evaluation of the efficiency of human immune system reconstitution in NSG mice and NSG mice containing a human HLA.A2 transgene using hematopoietic stem cells purified from different sources.

Authors:  John Patton; Raja Vuyyuru; Amanda Siglin; Michael Root; Tim Manser
Journal:  J Immunol Methods       Date:  2015-03-14       Impact factor: 2.303

Review 6.  Current advances in humanized mouse models.

Authors:  Ryoji Ito; Takeshi Takahashi; Ikumi Katano; Mamoru Ito
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

Review 7.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

8.  Development of functional human immune system with the transplantations of human fetal liver/thymus tissues and expanded hematopoietic stem cells in RAG2-/-gamma(c)-/- MICE.

Authors:  S-Y Joo; B-K Choi; M J Kang; D Y Jung; K S Park; J B Park; G S Choi; J Joh; C H Kwon; G O Jung; S K Lee; S-J Kim
Journal:  Transplant Proc       Date:  2009-06       Impact factor: 1.066

9.  Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis.

Authors:  Richard B Bankert; Sathy V Balu-Iyer; Kunle Odunsi; Leonard D Shultz; Raymond J Kelleher; Jennifer L Barnas; Michelle Simpson-Abelson; Robert Parsons; Sandra J Yokota
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

Review 10.  Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth.

Authors:  Kazuyoshi Shiga; Masayasu Hara; Takaya Nagasaki; Takafumi Sato; Hiroki Takahashi; Hiromitsu Takeyama
Journal:  Cancers (Basel)       Date:  2015-12-11       Impact factor: 6.639

View more
  90 in total

Review 1.  Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

Authors:  Kiera Rycaj; Hangwen Li; Jianjun Zhou; Xin Chen; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2017-04-11       Impact factor: 15.707

Review 2.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

Review 3.  Mouse models in hematopoietic stem cell gene therapy and genome editing.

Authors:  Stefan Radtke; Olivier Humbert; Hans-Peter Kiem
Journal:  Biochem Pharmacol       Date:  2019-11-06       Impact factor: 5.858

4.  The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.

Authors:  Laura L Stafman; Mary G Waldrop; Adele P Williams; Jamie M Aye; Jerry E Stewart; Elizabeth Mroczek-Musulman; Karina J Yoon; Kimberly Whelan; Elizabeth A Beierle
Journal:  J Pediatr Surg       Date:  2019-02-28       Impact factor: 2.545

5.  Contribution of Human Lung Parenchyma and Leukocyte Influx to Oxidative Stress and Immune System-Mediated Pathology following Nipah Virus Infection.

Authors:  Olivier Escaffre; Tais B Saito; Terry L Juelich; Tetsuro Ikegami; Jennifer K Smith; David D Perez; Colm Atkins; Corri B Levine; Matthew B Huante; Rebecca J Nusbaum; Janice J Endsley; Alexander N Freiberg; Barry Rockx
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

6.  Oxidant stress induction and signalling in xenografted (human breast cancer-tissues) plus estradiol treated or N-ethyl-N-nitrosourea treated female rats via altered estrogen sulfotransferase (rSULT1E1) expressions and SOD1/catalase regulations.

Authors:  Aarifa Nazmeen; Smarajit Maiti
Journal:  Mol Biol Rep       Date:  2018-10-12       Impact factor: 2.316

7.  Novel window for cancer nanotheranostics: non-invasive ocular assessments of tumor growth and nanotherapeutic treatment efficacy in vivo.

Authors:  Mayank Goswami; Xinlei Wang; Pengfei Zhang; Wenwu Xiao; Sarah J Karlen; Yuanpei Li; Robert J Zawadzki; Marie E Burns; Kit S Lam; Edward N Pugh
Journal:  Biomed Opt Express       Date:  2018-12-11       Impact factor: 3.732

Review 8.  Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models.

Authors:  Yan Ting Shue; Jing Shan Lim; Julien Sage
Journal:  Transl Lung Cancer Res       Date:  2018-02

Review 9.  Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

Authors:  Dingxiao Zhang; Dean G Tang; Kiera Rycaj
Journal:  Semin Cancer Biol       Date:  2018-05-09       Impact factor: 15.707

10.  Cross-Cancer Analysis Reveals Novel Pleiotropic Associations-Response.

Authors:  Rayjean J Hung; Gordon Fehringer; Graham Casey; Stephen B Gruber; Ulrike Peters; Ellen L Goode; Thomas A Sellers; Christopher A Haiman; David J Hunter; Peter Kraft; Christopher I Amos; Matthew L Freedman; Michael D Wilson
Journal:  Cancer Res       Date:  2017-10-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.